| Ticker: MCDE | 850 Maude Avenue | |
| Exchange: NASDAQ-National Market | Mountain View, California 94043 | |
| Industry: Service | (415) 428-1550 |
| Type of Shares: | Common Shares | Filing Date: | 3/18/96 | |
| U.S. Shares: | 2,500,000 | Offer Date: | 5/14/96 | |
| Non-U.S. Shares: | 0 | Filing Range: | $12.00 - $14.00 | |
| Primary Shares: | 2,500,000 | Offer Price: | $14.00 | |
| Secondary Shares: | 0 | Gross Spread: | $0.98 | |
| Offering Amount: | $32,500,000 | Selling: | $0.58 | |
| Expenses: | $800,000 | Reallowance: | $0.10 | |
| Shares Out After: | 10,256,981 |
| Manager | Tier | Phone |
| Merrill Lynch & Co. | Lead Manager | (212) 449-4600 |
| Alex. Brown & Sons Incorporated | Co-manager | (410) 727-1700 |
| Cowen & Company | Co-manager | (212) 495-6000 |
| Auditor: Ernst & Young | |||||
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 3/31/96 | 3/31/95 | 3/31/96 | ||
| Revenue: | $4.99 | $2.63 | $0.00 | Assets: | $20.69 |
| Net Income: | -$3.52 | $0.38 | -$1.79 | Liabilities: | $6.09 |
| EPS: | -$0.44 | $0.04 | -$0.22 | Equity: | $14.60 |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| Microcide is a biopharmaceutical company founded to discover, develop and commercialize novel antibiotics for the treatment of serious bacterial infections. Microcide's Targeted Antibiotics programs seek to rapidly develop clinically useful antibiotics tailored to treat specific bacterial infections, as well as antibiotic potentiators, which will overcome resistance pathways and restore usefulness to existing antibiotics that have been rendered ineffective. The specific problematic bacteria being addressed by the Company are responsible for 44% of the approximately two million hospital-acquired infections occurring annually in the United States. Microcide's Targeted Genomics programs seek to identify the pharmaceutically relevant portion of bacterial genomes that are essential to bacterial viability in vitro or to bacterial growth and virulence in vivo. |
| Use of Proceeds |
| The proceeds from the offering will be used to fund research and development and for general corporate purposes. |
©1996 IPO Data Systems, Inc. - All rights reserved.